TYRX has announced that it has received a license from Health Canada to market its new AIGISRx R Fully Resorbable Antibacterial Envelope. The AIGISRx R Antibacterial Envelope is specifically designed to stabilise implantable electronic devices IEDs while also releasing antimicrobial agents to help provide protection from microbial colonisation of the device during surgical implantation.
“Canada will be the first market in the world to gain access to our next generation AIGISRx Antibacterial Envelope technology,” commented Robert White, president and CEO, TYRX. “The AIGISRx R technology includes all of the advantages of the original AIGISRx, such as stability and infection reduction, but now with the added benefit of being fully resorbable.”
The AIGISRx R Envelope is intended to hold the implantable electronic devices, such as pacemakers and implantable cardioverter defibrillators (ICDs) securely in place in order to provide a stable environment when implanted in the body.
Additionally, the AIGISRx R contains the antimicrobial agents rifampin and minocycline, which are released over a 7 to10 day period, in order to help provide protection from microbial colonisation of the device during surgical implantation.
“Due to the continued increase in surgical site infections associated with cardiac implantable electronic devices (CIEDs), we are very pleased to have access to the AIGISRx R Antibacterial Envelope. We hope that AIGISRx R will serve as a key technology in addressing the significant impact that surgical site infections have on patient morbidity, mortality, and health care system costs,” said Peter Guerra, head of electrophysiology at the Montreal Heart Institute, Canada.
